Member Info for Matml74

Not sure if serious! There was a presentation last week which outlined the completion dates for the sprinter trial and it wasn't October.

1) if 80% of patients subscribed, does this mean the data has been analysed already and will speed up the end the point

The trial is double blinded so no data is seen by the company until after completion of the dosing phase. There is a Data and safety monitoring committee who will be seeing the data but they will not be reporting this to the company unless there were issues around safety.

2) Is RM cagey because he has seen the data and cant risk the reputation of SNG by letting the cat out the bag (positive or negative)

NO

3) Supply chain is ready to go, so does he know its imminent?

They raised funds in October 2020 for manufacture and supply so this needed to be done.

4) Has this data for the 80% been shared with US activ trial? NO

The LG CHEM affirmer PD L1 inhibitor is targeting a $6 billion market and growing. Looks like late 2022/23 this partnership will get the affirmer PD L1 inhibitor into the clinic and then the cash will really start to flow.

https://www.prnewswire.com/news-releases/global-pd-l1-nsclc-market-insights-epidemiology-drugs-and-players-2017-2030-301107521.html

SYN,

Agree, however I think Activ-2 progression is very significant. The difference with Activ 2 compared to our P2 home trial is that the yanks have been measuring viral load reduction when SNG001 is given early in the infection. If these numbers are excellent and there is significant viral load reduction then this is a major win for the drug and hopefully the market will pick up on this. Would provide confidence to investors that P3 has a high chance of success.

"As of September 2021 LG Chem has a market cap of $52.78 Billion. This makes LG Chem the world's 346th most valuable company by market cap according to our data. "

Love partners like that!

"The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totaling $98.5m for two therapeutics to be developed using the Affimer XT technology. Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.

The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products."

Excellent news. So many catalysts for SP growth with this stock. Sooner or later one of the big guys will come in and take the lot at a significant premium to where the company is at now.

Whilst the gold equivalent numbers won't change much as has been hinted by SD, there will be a lot of information in the PFS that we don't know yet, ASIC/CAPEX etc,etc,etc. Currently brokers, institutions and others have used assumed numbers for these parameters in their models...... that is where the potential upside around the PFS could come from.

Ok you got me to bite. The data is telling a different story.

Worldwide daily covid deaths at present are at 7.5k per day higher than they were last November before anyone had even been doses with a vaccine.

- US running at 80k hospitalisations per day.
- Over half of US states have no ICU beds available.

I could go on and on with more examples....... however if you did truly feel that way about the covid situation, and you truly did have a significant holding, which I highly doubt, why would you not sell up given your belief that covid is diminishing. Doesn’t make any investment sense to me.

Gunto, Well I don't see where he says EUA he says "regulatory approval".

Emergency use authorisation is different to full regulatory approval. In the case of the Pfizer vaccine it received FDA EUA 11th December, 2020 and full approval 23rd August.

Each and every country has their own methods/timeframes for the regulatory process.

Once we can see some data then there will be a clearer picture of the regulatory way forward.

AL, the device in SNG’s case is the nebuliser.

Thank you mstar. Had not seen that document before. Preclinical data looks good. Looking forward to seeing P1 data next year.

Agree BeContrarian, Progression in Activ-2 would be huge. At the very least it would show that the drug significantly reduces viral load and that it can be used effectively in the home environment to do this. A huge result for the company if this is the case. A significant re-rate would be in order.

It is not up to the company or CEO to manage the share price. In fact they have no control over it. The market does. It is up to the company/CEO to grow the business. If they do that correctly the SP will increase. Anyone who has followed this company closely knows that B/E and profitability is coming 2023 and there are significant growth opportunities, if SEE can win the contracts, to be a major player in the DMS market. Worrying about a penny or 2 movement here is pointless IMO.

Are you serious? It was in Melbourne about 4500km away.

All the major hires in place now. All with exceptional Pharma experience. Set for a transformative 6 months for SNG.

Does seem that way Dibs. Hopefully next TR1 is Polygon at 15%.

From Open Orphan RNS this morning.

"Post-pandemic, the infectious and respiratory disease market is seeing exponential growth, with an expected global market value of $250bn by 2025."

Might need to take this into buyout price considerations.

It is interesting kiwi but lets be realistic here. There is no way a chart can predict when an rns will drop. A chart monitors the sentiment of the herd.

Matterhorn, ‘Cancel culture’ Not even sure what that is. I just call out BS when I see it. If you read my posts correctly I stated that there will be interim results this month, which they neglected to even consider, when everyone can see exactly what the cash position of SNG is and make a considered analysis then. This was followed up by a BS bot generated article to back up their post.

The post was aimed at seeding doubt in investors minds. Simple!